| Rita Jauod Malones, | |
|
20 Chestnut Ave, Pompton Lakes, NJ 07442-2406 | |
| (973) 224-3022 | |
| (973) 383-0628 |
| Full Name | Rita Jauod Malones |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Gerontology |
| Location | 20 Chestnut Ave, Pompton Lakes, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275096869 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SG0600X | Clinical Nurse Specialist - Gerontology | 26NJ00907700 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rita Jauod Malones, 20 Chestnut Ave, Pompton Lakes, NJ 07442-2406 Ph: (973) 224-3022 | Rita Jauod Malones, 20 Chestnut Ave, Pompton Lakes, NJ 07442-2406 Ph: (973) 224-3022 |
News Archive
Researchers at Karolinska Institutet have discovered the underlying cause of a hereditary muscle disease first characterised in a Swedish family in 1980. It proves to be the first identified disease caused by defective myoglobin, the protein that transports oxygen in muscle cells.
Today Intercell AG announced that it has agreed with Novartis to advance Intercell's investigational Pseudomonas aeruginosa vaccine into a confirmatory clinical efficacy trial in ventilated ICU patients.
ADMA Biologics, Inc. (ADMA), a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that the first patient enrolled in the pivotal Phase III clinical study of its RI-002 has been dosed.
Cellectis bioresearch, the genome customization specialist and a commercial subsidiary of Cellectis, and Lonza, a world leader in biotechnology production, announce today that they have reached a significant milestone in the development of a newly bioengineered cell line.
POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced today the results of a Phase 1 study, which reported that PA32540, a novel coordinated-delivery tablet of enteric-coated aspirin (325 mg) and immediate-release omeprazole (40 mg), showed no ex vivo drug-drug interaction with clopidogrel when administered 10 hours apart in healthy patients, based on the study's pre-specified analysis.
› Verified 7 days ago